Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma

<i>Background:</i> Recent advances in the development of tyrosine kinase inhibitors (TKIs) have enabled patients with unresectable hepatocellular carcinoma (HCC) to receive multiple TKIs in sequence. The aim of this study was to identify predictors of good candidates for second-line trea...

Full description

Bibliographic Details
Main Authors: Hitomi Takada, Masayuki Kurosaki, Kaoru Tsuchiya, Yasuyuki Komiyama, Jun Itakura, Yuka Takahashi, Hiroyuki Nakanishi, Yutaka Yasui, Nobuharu Tamaki, Chiaki Maeyashiki, Shun Kaneko, Kenta Takaura, Mayu Higuchi, Mao Okada, Wan Wang, Leona Osawa, Shuhei Sekiguchi, Yuka Hayakawa, Koji Yamashita, Nobuyuki Enomoto, Namiki Izumi
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
hepatocellular carcinoma
tyrosine kinase inhibitor
Child–Pugh score
albumin–bilirubin grade
Online Access:https://www.mdpi.com/2072-6694/11/9/1256

Internet

https://www.mdpi.com/2072-6694/11/9/1256

Similar Items